OBJECTIVE: Several studies have shown evidence of executive function impairment associated with substance abuse. This suggests the potential usefulness of a baseline assessment measure to screen for dysexecutive impairments in individuals beginning treatment. The Dysexecutive Questionnaire (DEX) is a test widely used to estimate executive dysfunction. The main objective of this work is to study the psychometric properties of the Spanish version of the Dysexecutive Questionnaire (DEX-Sp). A complementary goal is to study its potential utility for initial screening in addicted individuals seeking treatment. METHOD: A sample of 131 non-clinical and 127 clinical individuals meeting the DSM-IV-TR substance abuse or dependence criteria were recruited. RESULTS: Internal consistency of the questionnaire was assessed (Cronbach's Alfa=0.91), as well as other reliability indicators. Exploratory and confirmatory factor analysis offers four- and five-factor solutions. Also tested were the dimensionality and structural model and its convergent and discriminant validity with other instruments. Differences between clinical and non-clinical individuals and total scores were also analyzed. CONCLUSIONS: The data suggest that the Spanish version of the DEX is a useful measure for assessing general symptoms of dysexecutive syndrome, and a valid, reliable and adequate screening test for estimating cognitive impairment associated with substance abuse.
OBJECTIVE: Several studies have shown evidence of executive function impairment associated with substance abuse. This suggests the potential usefulness of a baseline assessment measure to screen for dysexecutive impairments in individuals beginning treatment. The Dysexecutive Questionnaire (DEX) is a test widely used to estimate executive dysfunction. The main objective of this work is to study the psychometric properties of the Spanish version of the Dysexecutive Questionnaire (DEX-Sp). A complementary goal is to study its potential utility for initial screening in addicted individuals seeking treatment. METHOD: A sample of 131 non-clinical and 127 clinical individuals meeting the DSM-IV-TR substance abuse or dependence criteria were recruited. RESULTS: Internal consistency of the questionnaire was assessed (Cronbach's Alfa=0.91), as well as other reliability indicators. Exploratory and confirmatory factor analysis offers four- and five-factor solutions. Also tested were the dimensionality and structural model and its convergent and discriminant validity with other instruments. Differences between clinical and non-clinical individuals and total scores were also analyzed. CONCLUSIONS: The data suggest that the Spanish version of the DEX is a useful measure for assessing general symptoms of dysexecutive syndrome, and a valid, reliable and adequate screening test for estimating cognitive impairment associated with substance abuse.
Authors: Luis F Antón-Toro; Ricardo Bruña; Alberto Del Cerro-León; Danylyna Shpakivska; Patricia Mateos-Gordo; Claudia Porras-Truque; Raquel García-Gómez; Fernando Maestú; Luis Miguel García-Moreno Journal: Addict Biol Date: 2022-07 Impact factor: 4.093
Authors: Adrià Bermudo-Gallaguet; Mar Ariza; Rosalia Dacosta-Aguayo; Daniela Agudelo; Neus Camins-Vila; Maria Boldó; Òscar Carrera; Sandra Vidal; Blai Ferrer-Uris; Albert Busquets; Marc Via; Guillem Pera; Cynthia Cáceres; Meritxell Gomis; Alberto García-Molina; José María Tormos; Ana Arrabé; Gustavo Diez; Maria José Durà Mata; Pere Torán-Monserrat; Juan José Soriano-Raya; Sira Domènech; Alexandre Perera-Lluna; Kirk I Erickson; Maria Mataró Journal: Front Aging Neurosci Date: 2022-09-29 Impact factor: 5.702